

Infectious Disease Endorsement Maintenance 2012: NQF-Endorsed[®] Maintenance Standards

Table of Infectious Disease Measures

Maintenance measures to be reviewed in this project are highlighted in orange.
 Measures in which the developer has requested retirement are highlighted in green.
 Currently endorsed measures that are not being reviewed in this project are in white.
 Newly submitted measures to be reviewed in this project are highlighted in purple.

Measure Number	Title	Description	Measure Steward
0058	Avoidance of antibiotic treatment in adults with acute bronchitis	The percentage of adults 18–64 years of age with a diagnosis of acute bronchitis who were not dispensed an antibiotic prescription	National Committee for Quality Assurance (NCQA)
0069	Appropriate treatment for children with upper respiratory infection (URI)	Percentage of children who were given a diagnosis of URI and were not dispensed an antibiotic prescription on or three days after the episode date	National Committee for Quality Assurance (NCQA)
1746	Intrapartum Antibiotic Prophylaxis for Group B Streptococcus (GBS)	Percentage of pregnant women who are eligible for and receive appropriate intrapartum antibiotic prophylaxis (IAP) for Group B Streptococcus (GBS)	Massachusetts General Hospital
0431	INFLUENZA VACCINATION COVERAGE AMONG HEALTHCARE PERSONNEL	Percentage of healthcare personnel (HCP) who receive the influenza vaccination.	Centers for Disease Control and Prevention

Measure Number	Title	Description	Measure Steward
0039	Flu Shots for Adults Ages 50 and Over	"This measure represents the percentage of adults aged 50 and over who received an influenza vaccine within the measurement period within the respective age-stratified CAHPS surveys. This measure is only reported by age group stratification. The terms FSA and FSO, defined below, will be used to identify any differences between the two age stratifications.	National Committee for Quality Assurance
0040	Flu Shot for Older Adults	Percentage of patients age 65 and over who received an influenza vaccination from September through December of the year	National Committee for Quality Assurance
0041	Influenza Immunization	Percentage of patients aged 6 months and older seen for a visit between October 1 and the end of February who received an influenza immunization OR patient reported previous receipt of an influenza immunization	American Medical Association - Physician Consortium for Performance Improvement
0149	Influenza vaccination	Percentage of patients discharged during October, November, December, January, or February with pneumonia, age 50 and older, who were screened for influenza vaccine status and were vaccinated prior to discharge, if indicated	Centers for Medicare & Medicaid Services
0522	Influenza Immunization Received for Current Flu Season (Home Health)	Percentage of home health episodes of care during which patients received influenza immunization for the current flu season.	Centers for Medicare & Medicaid Services
0226	Influenza Immunization in the ESRD Population (Facility Level)	Percentage of end stage renal disease (ESRD) patients aged 6 months and older receiving hemodialysis or peritoneal dialysis during the time from October 1 (or when the influenza vaccine became available) to March 31 who either received, were offered and declined, or were determined to have a medical contraindication to the influenza vaccine.	Kidney Care Quality Alliance
0227	Influenza Immunization	Percentage of patients aged 18 years and older with a diagnosis of ESRD and receiving dialysis who received the influenza immunization during the flu season (September through February)	American Medical Association - Physician Consortium for Performance

Measure Number	Title	Description	Measure Steward
			Improvement
1659	Influenza Immunization	Inpatients age 6 months and older discharged during October, November, December, January, February or March who are screened for influenza vaccine status and vaccinated prior to discharge if indicated.	Centers for Medicare & Medicaid Services
0038	Childhood Immunization Status	Percentage of children 2 years of age who had four diphtheria, tetanus and acellular pertussis (DtaP); three polio (IPV); one measles, mumps and rubella (MMR); three H influenza type B (HiB); three hepatitis B (HepB); one chicken pox (VZV); four pneumococcal conjugate (PCV); two hepatitis A (HepA); two or three rotavirus (RV); and two influenza (flu) vaccines by their second birthday. The measure calculates a rate for each vaccine and nine separate combination rates.	National Committee for Quality Assurance
0680	Percent of Residents or Patients Who Were Assessed and Appropriately Given the Seasonal Influenza Vaccine (Short-Stay)	<p>"The measure reports the percentage of residents or patients who are assessed and appropriately given the influenza vaccine.</p> <p>This measure will include only residents or patients 6 months of age or older in the denominator. The measure is based on data from the Minimum Data Set (MDS) 3.0 assessments of nursing home residents, Inpatient Rehabilitation Facility Patient Assessment Instrument (IRF-PAI) assessments for Inpatient Rehabilitation Facility (IRF) patients, and the Long-Term Care Hospital (LTCH) Continuity Assessment Record & Evaluation (CARE) Data Set assessments of LTCH patients.</p> <p>Data are collected in each of these three settings using items that have been harmonized across the three assessment instruments. For the nursing home residents, the measure is limited to short-stay residents, defined as residents who are discharged within the first 100 days of their stay. For the IRFs and LTCHs, the measure will include all patients, irrespective of patient's length of stay.</p> <p>In 2008, the NQF steering committee met to identify voluntary consensus measures for influenza and pneumococcal vaccinations that were harmonized across healthcare settings. The steering committee recognized that "in the interest of standardization and minimizing burden for those implementing and using measures, measure harmonization is an important consideration in evaluating and recommending measures for endorsement." The committee supported the use of measure IM-016-07 which [at the time of the meeting] reported the percent of</p>	Centers for Medicare & Medicaid Services

Measure Number	Title	Description	Measure Steward
		<p>nursing home/skilled nursing facility residents given the influenza vaccination during the flu season, stratified by short- and long-stay patients using MDS 2.0 items as the basis for a harmonized influenza vaccination measure across healthcare settings (National Quality Forum, 2008a).</p> <p>The specifications of the proposed measure mirror those of the harmonized measure endorsed by the National Quality Forum (NQF) under measure number 0432 Influenza Vaccination of Nursing Home/Skilled Nursing Facility Residents (National Quality Forum, 2008b), with the addition of two additional patient care facilities -- IRFs and LTCHs. The NQF standard specifications were developed to achieve a uniform approach to measurement across patient care settings and populations by addressing who is included in and excluded from the target denominator population, who is included in and excluded from the numerator population, time window for measurement and time window for vaccinations.</p> <p>National Quality Forum (2008a, June). Revised voting draft for national voluntary consensus standards for influenza and pneumococcal immunizations. Received from Health Services Advisory Group on August 19, 2011.</p> <p>National Quality Forum. (2008b, December). National voluntary consensus standards for influenza and pneumococcal immunizations. Available from http://www.qualityforum.org/Publications/2008/12/National_Voluntary_Consensus_Standards_for_Influenza_and_Pneumococcal_Immunizations.aspx</p>	
0681	Percent of Residents Assessed and Appropriately Given the Seasonal Influenza Vaccine (Long-Stay)	<p>"This measure is based on data from the MDS 3.0 assessment of long-stay nursing facility residents and reports the percentage of all long-stay residents who were assessed and appropriately given the seasonal influenza vaccine during the influenza season. The measure reports on the percentage of residents who were assessed and appropriately given the seasonal influenza vaccine (MDS items O0250A and O250C) on the target MDS assessment (which may be an admission, annual, quarterly, significant change or correction assessment).</p> <p>Long-stay residents are those residents who have been in the nursing facility at least 100 days. The measure is restricted to the population with long-term care needs and does not include the short-stay population who are discharged within</p>	Centers for Medicare & Medicaid Services

Measure Number	Title	Description	Measure Steward
		<p>100 days of admission.</p> <p>This specification of the proposed measure mirrors the harmonized measure endorsed by the National Quality Forum (Measure number 0432: Influenza Vaccination of Nursing Home/Skilled Nursing Facility Residents.) The NQF standard specifications were developed to provide a uniform approach to measurement across settings and populations. The measure harmonizes who is included in the target denominator population, who is excluded, who is included in the numerator population, and time windows for measurement and vaccinations."</p>	
0298	Central line bundle compliance	<p>Percentage of intensive care patients with central lines for whom all elements of the central line bundle are documented and in place.</p> <p>The central line bundle elements include:</p> <ul style="list-style-type: none"> •Hand hygiene , •Maximal barrier precautions upon insertion •Chlorhexidine skin antisepsis •Optimal catheter site selection, with subclavian vein as the preferred site for non-tunneled catheters in patients 18 years and older •Daily review of line necessity with prompt removal of unnecessary lines 	Institute for Healthcare Improvement
0302	Ventilator bundle	<p>Percentage of intensive care unit patients on mechanical ventilation at time of survey for whom all four elements of the ventilator bundle are documented and in place. The ventilator bundle elements are:</p> <ul style="list-style-type: none"> •Head of bed (HOB) elevation 30 degrees or greater (unless medically contraindicated); noted on 2 different shifts within a 24 hour period •Daily "sedation interruption" and daily assessment of readiness to extubate; process includes interrupting sedation until patient follow commands and patient is assessed for discontinuation of mechanical ventilation; Parameters of discontinuation include: resolution of reason for intubation; inspired oxygen content roughly 40%; assessment of patients ability to defend airway after extubation due to heavy sedation; minute ventilation less than equal to 15 liters/minute; and respiratory rate/tidal volume less than or equal to 105/min/L(RR/TV< 105) •SUD (peptic ulcer disease) prophylaxis •DVT (deep venous thrombosis) prophylaxis 	Institute for Healthcare Improvement
0393	Hepatitis C: Testing for chronic hepatitis C- Confirmation of hepatitis C viremia	Percentage of patients aged 18 years and older with a diagnosis of hepatitis C seen for an initial evaluation who had HCV RNA testing ordered or previously performed	American Medical Association – Physician Consortium for Performance Improvement (AMA-PCPI)

Measure Number	Title	Description	Measure Steward
0394	Hepatitis C: Counseling regarding use of contraception prior to antiviral treatment	Percentage of female patients aged 18 to 44 years and all men aged 18 years and older with a diagnosis chronic hepatitis C who are receiving antiviral treatment who were counseled regarding contraception prior to the initiation of antiviral treatment	American Medical Association – Physician Consortium for Performance Improvement (AMA-PCPI)
0395	Hepatitis C RNA testing before initiating treatment *paired with 0396	Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C who are receiving antiviral treatment for whom quantitative HCV RNA testing was performed within 6 months prior to initiation of antiviral treatment	American Medical Association – Physician Consortium for Performance Improvement (AMA-PCPI)
0584	Hepatitis C: Viral load test	This measure identifies the percentage of patients with Hepatitis C (HCV) who began HCV antiviral therapy during the measurement year and had HCV Viral Load testing prior to initiation of antiviral therapy	Resolution Health, Inc.
0396	HCV Genotype testing prior to treatment *paired with 0395	Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C who are receiving antiviral treatment for whom HCV genotype testing was performed within 6 months prior to initiation of antiviral treatment	American Medical Association – Physician Consortium for Performance Improvement (AMA-PCPI)
0397	Hepatitis C: Prescribed antiviral therapy	Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C who were prescribed peginterferon and ribavirin therapy within the 12 month reporting period	American Medical Association – Physician Consortium for Performance Improvement (AMA-PCPI)
0398	Hepatitis C: HCV RNA testing at week 12 of treatment	Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C who are receiving antiviral treatment for whom quantitative HCV RNA testing was performed at 12 weeks from initiation of antiviral treatment	American Medical Association – Physician Consortium for Performance Improvement (AMA-PCPI)
0399	Hepatitis C: Hepatitis A vaccination	Percentage of patients aged 18 years and older with a diagnosis of hepatitis C who have received hepatitis A vaccination, or who have documented immunity	American Medical Association – Physician Consortium for Performance

Measure Number	Title	Description	Measure Steward
	*paired with 0400		Improvement (AMA-PCPI)
0400	Hepatitis C: Hepatitis B vaccination *paired with 0399	Percentage of patients aged 18 years and older with a diagnosis for hepatitis C who have received hepatitis B vaccination, or who have documented immunity	American Medical Association – Physician Consortium for Performance Improvement (AMA-PCPI)
0401	Hepatitis C: Counseling regarding risk of alcohol consumption	Percentage of patients aged 18 years and older with a diagnosis of hepatitis C who received counseling regarding the risk of alcohol consumption at least once within the 12 month reporting period	American Medical Association – Physician Consortium for Performance Improvement (AMA-PCPI)
0635	Chronic Liver Disease - Hepatitis A Vaccination	The percentage of adult patients with chronic liver disease who have received a hepatitis A vaccine	ActiveHealth Management
0475	Hepatitis B Vaccine Coverage Among All Live Newborn Infants Prior to Hospital or Birthing Facility Discharge	Percent of live newborn infants that receive hepatitis B vaccination before discharge at each single hospital/birthing facility during given time period (one year).	Centers for Disease Control and Prevention
2081	Newly enrolled in medical care	Percentage of patients, regardless of age, with a diagnosis of HIV who were newly enrolled and had a medical visit in each of the 4-month periods in the measurement year	Health Resources and Services Administration - HIV/AIDS Bureau
0403	HIV/AIDS: Medical visit	Percentage of patients, regardless of age, with a diagnosis of HIV/AIDS with at least one medical visit in each 6 month period with a minimum of 60 days between each visit	National Committee for Quality Assurance (NCQA)

Measure Number	Title	Description	Measure Steward
2079	Medical visit frequency	Percentage of patients, regardless of age, with a diagnosis of HIV who had at least one medical visit in each 6-month period of the 24-month measurement period with a minimum of 60 days between medical visits	Health Resources and Services Administration - HIV/AIDS Bureau
2080	Gap in medical visits	Percentage of patients, regardless of age, with a diagnosis of HIV who did not have a medical visit in the last 6 months of the measurement year	Health Resources and Services Administration - HIV/AIDS Bureau
0404	HIV/AIDS: CD4+ cell count or CD4+ percentage	Percentage of patients, regardless of age, with a diagnosis of HIV/AIDS with a CD4+ cell count or CD4+ cell percentage performed at least once every 6 months	National Committee for Quality Assurance (NCQA)
0405	HIV/AIDS: Pneumocystis jiroveci pneumonia (PCP) prophylaxis	Percentage of patients aged 1 month or older who were prescribed Pneumocystis jiroveci pneumonia (PCP) prophylaxis	National Committee for Quality Assurance (NCQA)
0406	HIV/AIDS: Adolescent and adult patients with HIV/AIDS who are prescribed potent antiretroviral therapy	Percentage of patients with a diagnosis of HIV/AIDS with at least two visits during the measurement year, with at least 60 days between each visit: aged 13 years and older who have a history of a nadir CD4+ count below 350/mm ³ ; aged 13 years and older who have a history of an AIDS-defining illness, regardless of CD4+ count; or who are pregnant, regardless of CD4+ count or age, who were prescribed potent antiretroviral therapy	National Committee for Quality Assurance (NCQA)
0407	HIV/AIDS: HIV RNA control after six months of potent antiretroviral therapy	<p>Percentage of patients aged 13 years and older with a diagnosis of HIV/AIDS who had at least two medical visits during the measurement year, with at least 60 days between each visit, who are receiving potent antiretroviral therapy^{***}, who have a viral load below limits of quantification* after at least 6 months of potent antiretroviral therapy^{***} OR whose viral load is not below limits of quantification* after at least 6 months of potent antiretroviral therapy and has documentation of a plan of care^{**}</p> <p>*Using laboratory cutoff level for reference laboratory used by that clinic or provider **A plan of care may include: altering the therapy regimen, reaffirming to the patient the importance of high adherence to the regimen, or reassessment of viral load at a specified future date *** Potent antiretroviral therapy is described as any antiretroviral therapy that has demonstrated optimal efficacy and results in durable suppression of HIV as shown by prior clinical trials</p>	National Committee for Quality Assurance (NCQA)

Measure Number	Title	Description	Measure Steward
2083	Prescription of HIV antiretroviral therapy	Percentage of patients, regardless of age, with a diagnosis of HIV prescribed antiretroviral therapy for the treatment of HIV infection during the measurement year	Health Resources and Services Administration - HIV/AIDS Bureau
2082	HIV viral load suppression	Percentage of patients, regardless of age, with a diagnosis of HIV with a HIV viral load less than 200 copies/mL at last HIV viral load test during the measurement year	Health Resources and Services Administration - HIV/AIDS Bureau
0408	HIV/AIDS: Tuberculosis (TB) screening	Percentage of patients aged 3 months and older with a diagnosis of HIV/AIDS for whom there was documentation that a tuberculosis (TB) screening test was performed and results interpreted at least once since the diagnosis of HIV infection	National Committee for Quality Assurance (NCQA)
0033	Chlamydia screening in women	Assesses the percentage of women 16–24 years of age who were identified as sexually active and who had at least one test for chlamydia during the measurement year.	National Committee for Quality Assurance
1395	Chlamydia Screening and Follow Up	Percentage of female adolescents 18 years of age who had a chlamydia screening test with proper follow-up	National Committee for Quality Assurance
0409	HIV/AIDS: Sexually transmitted disease- Chlamydia and gonorrhea screenings	Percentage of patients aged 13 years and older with a diagnosis of HIV/AIDS for whom chlamydia and gonorrhea screenings were performed at least once since the diagnosis of HIV infection	National Committee for Quality Assurance (NCQA)
0573	HIV SCREENING: MEMBERS AT HIGH RISK OF HIV	To ensure that members diagnosed or seeking treatment for sexually transmitted diseases be screened for HIV.	IMS Health
0410	HIV/AIDS: Sexually transmitted diseases-Syphilis screening (withdrawn from	Percentage of patients aged 13 years and older with a diagnosis of HIV/AIDS for whom syphilis screening was performed during the measurement year	National Committee for Quality Assurance (NCQA)

Measure Number	Title	Description	Measure Steward
	<p>consideration of endorsement-this measure has been combined with measure 0409)</p>		
0411	<p>HIV/AIDS: Other infectious diseases-Hepatitis B screening</p> <p>(withdrawn from consideration of endorsement-request for retirement by developer)</p>	<p>Percentage of patients for whom Hepatitis B screening was performed at least once since the diagnosis of HIV infection or for whom there is documented immunity</p>	<p>National Committee for Quality Assurance (NCQA)</p>
0412	<p>HIV/AIDS: Hepatitis B vaccination</p>	<p>Percentage of patients, regardless of age, with a diagnosis of HIV/AIDS who have received at least one hepatitis B vaccination, or who have documented immunity</p>	<p>National Committee for Quality Assurance (NCQA)</p>
0413	<p>HIV/AIDS: Screening for high risk sexual behaviors</p> <p>(withdrawn from consideration of endorsement-request for retirement by developer)</p>	<p>Percentage of patients, aged 13 years and older, who were screened for high risk sexual behaviors at least once within 12 months</p>	<p>National Committee for Quality Assurance (NCQA)</p>
0414	<p>HIV/AIDS: Other infectious diseases-Hepatitis C</p> <p>(withdrawn from consideration of endorsement-</p>	<p>Percentage of patients aged 13 years and older with a diagnosis of HIV/AIDS for whom Hepatitis screening was performed at least once since the diagnosis of HIV infection, or for whom there is documented immunity</p>	<p>National Committee for Quality Assurance (NCQA)</p>

Measure Number	Title	Description	Measure Steward
	request for retirement by developer)		
0415	HIV/AIDS: Screening for injection drug use (withdrawn from consideration of endorsement-request for retirement by developer)	Percentage of patients, aged 13 years and older, who were screened for injection drug use at least once within 12 months	National Committee for Quality Assurance (NCQA)
0568	Appropriate follow-up for patients with HIV (withdrawn from consideration of endorsement-request for retirement by developer)	To ensure that all members diagnosed with HIV receive at least annual testing for CD4 and at least biannual HIV RNA levels to monitor for disease activity	Health Benchmarks-IMS Health
1959	Human Papillomavirus Vaccine for Female Adolescents	Percentage of female adolescents 13 years of age who had three doses of the human papillomavirus (HPV) vaccine by their 13th birthday	National Committee for Quality Assurance
0500	Severe sepsis and septic shock: Management bundle	Initial steps in the management of the patient presenting with infection (severe sepsis or septic shock)	Henry Ford Hospital
0304	Late sepsis or meningitis in Very Low Birth Weight (VLBW) neonates	Standardized rate and standardized morbidity ratio for nosocomial bacterial infection after day 3 of life for very low birth weight infants, including infants with birth weights between 401 and 1500 grams and infants whose gestational age is between 22 and 29 weeks.	Vermont Oxford Network

Measure Number	Title	Description	Measure Steward
	(risk-adjusted)		
1716	National Healthcare Safety Network (NHSN) Facility-wide Inpatient Hospital-onset Methicillin-resistant Staphylococcus aureus (MRSA) Bacteremia Outcome Measure	Standardized infection ratio (SIR) of hospital-onset unique blood source MRSA Laboratory-identified events (LabID events) among all inpatients in the facility	Centers for Disease Control and Prevention
1717	National Healthcare Safety Network (NHSN) Facility-wide Inpatient Hospital-onset Clostridium difficile Infection (CDI) Outcome Measure	Standardized infection ratio (SIR) of hospital-onset CDI Laboratory-identified events (LabID events) among all inpatients in the facility, excluding well-baby nurseries and neonatal intensive care units (NICUs)	Centers for Disease Control and Prevention